EUVIMEDEUVIMED entdecken
Crossref

Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids

Ming Lei, Zhixiong Li, Chunsong Xiong, Fen Xie, Lingyan Liu, Dan He iD

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-026-04943-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Ming Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China. Hauptthemen laut MEDLINE: Ferroptosis, Trastuzumab, Organoids, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Key Project of the Health Commission of Hunan Province, Guiding Plan Project of Hengyang City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab is widely used for HER2-positive breast cancer, but its relationship with ferroptosis remains unclear. In this study, patient-derived breast cancer organoids were used to examine trastuzumab-associated ferroptosis-related changes and the possible involvement of p53 signaling. Three independent HER2-positive breast cancer organoid lines were used for the main functional experiments, and three HER2-low organoid lines were included as control models. The IC50-based working concentration of trastuzumab was 66.31 µg/mL. Transcriptome analysis revealed enrichment of ferroptosis- and p53-related pathways after trastuzumab treatment. In HER2-positive organoids, trastuzumab reduced organoid viability and altered organoid morphology, accompanied by increased MDA, Fe²⁺, and ROS levels and decreased GSH/GSSG, SLC7A11, and GPX4 expression. The same treatment did not produce comparable changes in HER2-low organoids. Fer-1 partially attenuated the changes in organoid viability and ferroptosis-related indicators. PFT-α showed a similar partial rescue effect. In addition, p53 knockdown weakened several trastuzumab-associated changes, including alterations in viability, oxidative stress-related markers, and SLC7A11/GPX4 expression. These findings suggest that trastuzumab treatment is associated with ferroptosis-related biochemical and molecular alterations in HER2-positive breast cancer organoids, and that p53-related signaling may participate in this process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisTrastuzumabOrganoidsErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleTumor Suppressor Protein p53Signal TransductionCell Line, TumorCell SurvivalReactive Oxygen SpeciesOxidative StressAmino Acid Transport System y+

Stichwörter der Autor:innen

FerroptosisHER2-positive breast cancerOrganoidsTrastuzumabp53 signaling

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53Antineoplastic Agents, ImmunologicalERBB2 protein, humanTP53 protein, humanReactive Oxygen SpeciesSLC7A11 protein, humanAmino Acid Transport System y+

Autor:innen und Institutionen

  • Department of Breast Surgery, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China.
  • Department of Anesthesiology, Hengyang Maternal and Child Health Hospital, No. 89, Jiefang Road, Yanfeng District, Hengyang, 421001, China.
  • Department of science and education, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China.
  • Department of Anesthesiology, Hengyang Maternal and Child Health Hospital, No. 89, Jiefang Road, Yanfeng District, Hengyang, 421001, China. Danny_ho@foxmail.com.

ORCID-Profile: Dan He

Förderung

  • Natural Science Foundation of Hunan Province
  • Key Project of the Health Commission of Hunan Province
  • Guiding Plan Project of Hengyang City

Zitieren

APA

Lei, M., Li, Z., Xiong, C., Xie, F., Liu, L., & He, D. (2026). Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04943-4

Vancouver

Lei M, Li Z, Xiong C, Xie F, Liu L, He D. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04943-4

BibTeX
@article{Lei2026,
  author = {Lei, Ming and Li, Zhixiong and Xiong, Chunsong and Xie, Fen and Liu, Lingyan and He, Dan},
  title = {Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-026-04943-4}
}
Kostenlos starten →